{
    "nct_id": "NCT03013218",
    "official_title": "A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)",
    "inclusion_criteria": "* Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..\n* Adequate Bone Marrow Function.\n* Adequate Renal & Liver Function.\n* Adequate Performance Status\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.\n* Previous high-dose chemotherapy requiring allogenic stem cell rescue.\n* Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.",
    "miscellaneous_criteria": ""
}